bluebird bio to Present LentiGlobin Clinical Data at 20th Congress of European Hematology Association
Research and Markets: Global Cell Therapy Market Outlook 2020
Research and Markets: Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025
Research and Markets: Global Oncology/Cancer Drugs Market 2015: Therapeutic Modalities, Cancer Types and Geography - Forecasts to 2020 for the $119 Billion Market
The Multiple Myeloma Research Foundation Raised $800,000 for Cancer Research at the 13th Annual Laugh for Life Event in New York City
Luspatercept Data Presented at the 13th International Symposium on Myelodysplastic Syndromes
Tuttle Tactical Management, LLC is an investment adviser registered with the U.S. Securities and Exchange Commission. You should not assume that any discussion or information contained in this letter serves as the receipt of, or as a substitute for, personalized investment advice from Tuttle Tactical Management, LLC. It is published solely for informational purposes and is not to be construed as a solicitation nor does it constitute advice, investment or otherwise. To the extent that a reader has questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional adviser of his/her choosing. A copy of our written disclosure statement regarding our advisory services and fees is available upon request. Our comments are an expression of opinion. While we believe our statements to be true, they always depend on the reliability of our own credible sources. Past performance is no guarantee of ...
Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...
Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.
Widening investment-grade credit spreads and rising interest rates lead to losses.